Steven G. Coca DO, MSAssociate Chair for Clinical and Translational Research, Department of Internal Medicine; Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
Steven G. Coca, DO, is a graduate of the University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in Connecticut. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. There, he later served as an Assistant Professor in the Section of Nephrology, until his recruitment to Mount Sinai in 2014 as Associate Professor. He is the Director for Clinical Research for the Division of Nephrology and is the Associate Chair for Clinical and Translational Research for the Department of Medicine at the Icahn School of Medicine at Mount Sinai.
His research has focused on using novel biomarkers to improve risk stratification in patients with acute kidney injury and patients at risk or with prevalent chronic kidney disease. He has been continually funded by the NIH over the last decade for multiple biomarker-related projects and consortia. He is the co-founder of RenalytixAI.
DisclosuresDr. Coca reports the following:
Consultancy Agreements: RenalytixAI, Takeda, CHF Solutions, Relypsa, Bayer, Boehringer Ingelheim, Quark, Akebia
Ownership Interest: RenalytixAI, pulseData
Research Funding: RenalytixAI, inRegen
Patents and Inventions: RenalytixAI
Scientific Advisor or Membership: RenalytixAI
Other Interests/Relationships: Associate Editor for Kidney360, Editorial Board JASN, CJASN, Kidney International
Recent Contributions to PracticeUpdate:
- Dapagliflozin in Patients With Chronic Kidney Disease
- SGLT2 Inhibition for the Prevention of Diabetic Kidney Disease
- Canagliflozin Improves Renal Outcomes in Type 2 Diabetes
- Effects of the SGLT2 Inhibitor Dapagliflozin on Glomerular and Tubular Injury Markers
- Long-Term Follow-Up of Intensive Glycemic Control on Renal Outcomes